Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence

Executive Summary

In a recent presentation on evidence-based reimbursement and personalized medicine, a Novartis executive highlights Medicare Part B contractor Palmetto GBA’s molecular diagnostic reimbursement initiative as one to watch.

You may also be interested in...

Medicare Part B: Commentary By CMS Officials

CMS officials Jonathan Blum, Louis Jacques and Tamara Jensen addressed a number of Medicare Part B-related topics of interest to the biopharmaceutical industry at the FDA/CMS Summit, including reimbursement for high-priced oncology drugs, coverage with evidence development and national coverage determinations.

Molecular Dx Reimbursement: Medicare Contractor Seeks Tighter Controls

The Medicare contractor that handles claims for California and several other states is taking steps to enhance its control over reimbursement of molecular diagnostic tests.

With Genoptix, Novartis Continues Its Diagnostics Build Up

Novartis is building a molecular diagnostics business, which can support its pharmaceutical business's aggressive expansion in targeted therapies.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts